Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?

Stroke

Volumn 33, Issue 9, 2002, Pages 2187-2191

  Chung, Natali A Y ^a   Belgore, Funmi ^a   Li Saw Hee, Foo Leong ^a   Conway, Dwayne S G ^a   Blann, Andrew D ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Angiogenesis; Atrial fibrillation; Thrombosis

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCOAGULABILITY; MALE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SINUS RHYTHM; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD PRESSURE; CASE-CONTROL STUDIES; CHRONIC DISEASE; CORONARY ARTERIOSCLEROSIS; CROSS-SECTIONAL STUDIES; DEMOGRAPHY; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; LYMPHOKINES; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; THROMBOPHILIA; THROMBOPLASTIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS; WARFARIN;

EID: 0036713987     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000023889.84649.3D     Document Type: Article

References (37)

1. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates
2. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study
3. Does atrial fibrillation confer a hypercoagulable state?
4. Pathogenetic mechanisms of thrombosis in malignancy
5. Changes of the coagulation and fibrinolysis system in malignancy: Their possible impact on future diagnostic and therapeutic procedures
6. Hemostasis in malignancy
7. The hemostatic system and angiogenesis in malignancy
8. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: Implications for measurement of circulating VEGF levels in clinical disease
9. Cooperation between VEGF and TNF-α is necessary for exposure of active tissue factor on the surface of human endothelial cells
10. Differences in free and total tissue factor pathway inhibitor, and tissue factor in peripheral artery disease compared to healthy controls
11. Vascular endothelial growth factor and its receptor Flt-1 in the plasma of patients with coronary and peripheral atherosclerosis and type II diabetes
12. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: Possible pathophysiological significance of VEGF in progression of atherosclerosis
13. Tissue factor in the pathogenesis of atherosclerosis
14. Tissue factor in atherosclerosis
15. Hemostatic state and atrial fibrillation (the Framingham Offspring Study)
16. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation
17. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation: Effects of cardioversion and return of left atrial function
18. Increased membrane and soluble P-selectin in atrial fibrillation
19. Plasma adenosine levels and platelet activation in patients with atrial fibrillation
20. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: A study in patients with paroxysmal atrial fibrillation
21. Cancer and the prothrombotic state
22. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients
23. Tissue factor and homocysteine levels in ischemic heart disease are associated with angiographically documented clinical recurrences after coronary angioplasty
24. Identification of active tissue factor in human coronary atheroma
25. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina
26. Increased plasma tissue factor levels in acute myocardial infarction
27. Tissue factor expression and angiogenesis in human prostate carcinoma
28. Serum levels of vascular endothelial growth factor and transforming growth factor-beta1 in patients with atrial fibrillation undergoing defibrillation therapy
29. Pitfalls in the measurement of circulating vascular endothelial growth factor
30. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension
31. Successful therapy reduces levels of vascular endothelial growth factor (VEGF) in patients with hypertension and patients with hypercholesterolemia
32. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor
33. Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: A role for tissue factor gene expression
34. Tissue factor: A receptor involved in the control of cellular properties, including angiogenesis
35. Vascular endothelial growth factor KDR receptor signaling potentiates tumor necrosis factor-induced tissue factor expression in endothelial cells
36. Activation of coagulation and angiogenesis in cancer: Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer
37. Atrial fibrillation impairs endothelial function of forearm vessels in humans